142 related articles for article (PubMed ID: 27994685)
1. Intra-patient Variability of FDG Standardized Uptake Values in Mediastinal Blood Pool, Liver, and Myocardium during R-CHOP Chemotherapy in Patients with Diffuse Large B-cell Lymphoma.
Kim SJ; Yi HK; Lim CH; Cho YS; Choi JY; Choe YS; Lee KH; Kim BT; Moon SH
Nucl Med Mol Imaging; 2016 Dec; 50(4):300-307. PubMed ID: 27994685
[TBL] [Abstract][Full Text] [Related]
2. The Association Between Liver and Tumor [
Wu X; Bhattarai A; Korkola P; Pertovaara H; Eskola H; Kellokumpu-Lehtinen PL
Mol Imaging Biol; 2017 Oct; 19(5):787-794. PubMed ID: 28144908
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma.
Ceriani L; Suriano S; Ruberto T; Zucca E; Giovanella L
Clin Nucl Med; 2012 Oct; 37(10):949-52. PubMed ID: 22955068
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of baseline
Zhu L; Meng Y; Guo L; Zhao H; Shi Y; Li S; Wang A; Zhang X; Shi J; Zhu J; Xu K
Oncol Lett; 2021 Feb; 21(2):132. PubMed ID: 33552253
[TBL] [Abstract][Full Text] [Related]
5. Effect of R-CHOP chemotherapy on liver and mediastinal blood pool (18)F-FDG standardized uptake values in patients with non-Hodgkin's lymphoma.
Kaya B; Dostbil Z; Ismailoglu M; Tasdemir B; Sahin O
Clin Imaging; 2015; 39(4):632-5. PubMed ID: 25709112
[TBL] [Abstract][Full Text] [Related]
6. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
Adams HJ; Kwee TC
Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
12. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
13. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
[TBL] [Abstract][Full Text] [Related]
14. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
[TBL] [Abstract][Full Text] [Related]
15. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
[TBL] [Abstract][Full Text] [Related]
17. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Metabolic Tumor Volume Estimated by (18) F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease.
Kim J; Hong J; Kim SG; Hwang KH; Kim M; Ahn HK; Sym SJ; Park J; Cho EK; Shin DB; Lee JH
Nucl Med Mol Imaging; 2014 Sep; 48(3):187-95. PubMed ID: 25177375
[TBL] [Abstract][Full Text] [Related]
19. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Kitajima K; Okada M; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Tamaki H; Fujimori Y; Ueda S; Kawamoto H; Taniguchi J; Yamakado K
Oncotarget; 2019 Sep; 10(52):5403-5411. PubMed ID: 31534626
[No Abstract] [Full Text] [Related]
[Next] [New Search]
